Anika Therapeutics (ANIK) Cost of Revenue (2010 - 2026)

Anika Therapeutics (ANIK) has reported Cost of Revenue for 17 consecutive years, with $11.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue fell 17.97% year-over-year to $11.4 million in Q2 2026; TTM through Jun 2026 was $45.6 million, a 6.78% decrease from a year earlier, with the FY2025 full-year figure at $49.0 million, up 11.62% from the prior year.
• Cost of Revenue was $11.4 million for Q2 2026 at Anika Therapeutics, up from $10.6 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $17.5 million in Q3 2022 and troughed at -$8.7 million in Q4 2023.
• A 5-year average of $10.8 million and a median of $11.9 million in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue plunged 137.1% in 2022 and jumped 255.4% in 2024, its largest moves.
• Over 5 years, Cost of Revenue stood at -$6.6 million in 2022, then plunged by 32.15% to -$8.7 million in 2023, then jumped by 255.4% to $13.5 million in 2024, then dropped by 15.14% to $11.4 million in 2025, then retreated by 0.61% to $11.4 million in 2026.
• The last three Cost of Revenue figures came in at $11.4 million (Q2 2026), $10.6 million (Q1 2026), and $11.4 million (Q4 2025), per Business Quant data.